Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary

August 8, 2024

NASDAQ US Health Care Pharmaceuticals earnings 46 min

Earnings Call Speaker Segments

Vivian Wu

executive
#1

Thanks, Crystal, and good afternoon to all of you. I appreciate everyone joining us today; participating on this call are our President and Chief Executive Officer, Howard Robin; our Chief Research and Development Officer, Dr. Jonathan Zalevsky; our Chief Medical Officer, Dr. Mary Tagliaferri; and our Chief Financial Officer, Sandra Gardiner. During this call, we anticipate making forward-looking statements about our business, including statements about the therapeutic potential of and future development plans for drug candidates and research programs. When clinical trials for drug candidates will begin and when clinical data will become available, when and how future clinical data presentations are planned, whether collaboration agreements will be formed and how they will develop or succeed, along with financial guidance and other statements about the business's future. Because forward-looking statements concern what has not yet happened, they carry uncertainties and risks that are hard to foresee, and many of these lie beyond our control. What we actually achieve could differ substantially from what these statements suggest. Significant risks and uncertainties appear in our Form 10-Q submitted on May 10, 2024, which can be found at sec.gov. We don't have any duty to revise these forward-looking statements—not because of fresh information, later events, or anything else. You'll be able to find a webcast of today's call on the investor relations section of Nektar's site, nektar.com. Having said that, I'll now turn things over to Howard Robin, our President and CEO. Howard?

Howard Robin

executive
#2

Thanks, Vivian, and I appreciate everyone being here today. During Q2, we moved closer to our objective of creating an extremely promising, best-in-class pipeline centered on inflammation and immunology. This quarter, we kept achieving meaningful strides with our lead candidate, Rezpegaldesleukin, also called REZPEG. REZPEG works by reducing inflammatory responses while at the same time rebalancing immunity — it does this through direct expansion of functional T-reg cells and by activating several immunoregulatory pathways in autoimmune patients. Promising results have come from REZPEG, backing its potential as a highly differentiated, novel therapy for immune conditions. Among those results are Phase Ib efficacy findings in atopic dermatitis — the most frequent chronic inflammatory skin condition, characterized by immune system dysregulation and, in particular, overactivation of autoreactive and inflammatory T-cells. REZPEG is built to tackle this pathway dysfunction — this dysregulation — by multiplying regulatory T-cells, which can simultaneously affect numerous inflammatory pathways. REZPEG is a first-in-class agent and the most clinically advanced program of its type aimed at atopic dermatitis, an area traditionally centered on signal pathway antagonists. I'll hand it to JZ to say more on that shortly, but I'm pleased to share that we have a forthcoming paper accepted by Nature Communications plus a presentation at the EADV Conference in September, both of which demonstrate REZPEG's mechanism. These publications will include comprehensive biomarker analyses from our Phase Ib trials in immune-driven skin conditions — atopic dermatitis and psoriasis. REZPEG is progressing well in the Phase IIb trials Nektar is running in atopic dermatitis and alopecia areata. Both trials remain on schedule for enrollment. The atopic dermatitis trial is enrolling 400 patients across roughly 110 clinical investigator sites in the U.S., Canada, Europe and Australia. Those entering the trial are diagnosed with moderate to severe atopic dermatitis, are biologic naive, and have not succeeded with topical treatment options. Importantly, this matches the exact patient population examined in the REZPEG Phase Ib trial. JZ will discuss the study design further later on the call. And as I mentioned, enrollment remains on track for a top line data readout from the study's 16-week induction treatment stage in the first half of 2025. Results from the maintenance stage, examining maintenance dosing every 4 weeks and every 12 weeks, should arrive toward the end of 2025 and in early '26. There is a substantial unmet need for distinctive new mechanisms to treat atopic dermatitis; given how extensive and broad the studies underway are right now, along with the competition for patient recruitment, I take pride in the fact that we're hitting our enrollment targets. We think this stems from a mix of the compelling REZPEG Phase Ib data shown at EADV 2023 and, naturally, the dedication of our clinical team. Within the U.S., about 30 million individuals are living with atopic dermatitis, and half of those patients receive a diagnosis of moderate-to-severe disease. It's thought that fewer than 10% of patients who are eligible for biologics at present actually get treated; our view is that novel mechanisms hold the key to expanding this market, and that a substantial unmet medical need exists for new treatment choices. That's why we're thrilled that REZPEG looks ready to stand out as a highly differentiated possible therapy for such patients. As everyone is aware, a second Phase II trial of REZPEG is now recruiting 84 individuals who have alopecia areata. This study began enrollment in March, and recruitment for it is likewise proceeding on schedule; we anticipate top line data from this trial in the middle of 2025, which should arrive a few months after the top line readout from the Phase II study in atopic dermatitis; in our view, REZPEG holds considerable promise for assisting people living with this devastating disease. Close to 7 million people in the U.S. by itself either have or will get alopecia areata. This condition has a major impact on patients' quality of life, and the JAK inhibitor therapies available right now lack durability, come with high relapse rates and pose meaningful safety risks. So an urgent unmet medical need exists for these new therapies; on the preclinical side, we keep moving NKTR-0165 forward, our novel TNFR2 agonist antibody program. During June, we shared the initial preclinical data for this program at EULAR. Those data demonstrate that NKTR-0165 is a unique antibody possessing monomeric activity that selectively binds to TNFR2 on Tregs, boosting their immunoregulatory function. Because TNFR receptor 2 matters in certain autoimmune diseases, NKTR-0165 has the potential to become a first-in-class therapy for autoimmune conditions including multiple sclerosis, ulcerative colitis, lupus and Vitiligo. Right now we're running IND-enabling studies, aiming to be ready for an IFD submission in the middle of 2025. Now I want to update you on NKTR-255, our IL-15 program in oncology. As you're aware, Nektar is wrapping up a study in large B-cell lymphoma, or LBCL, and Mary will cover this afterward in the call; beyond the clinical study we're finishing in LBCL, clinical studies for NKTR-255 are underway with funding from our collaborators, Merck KGA in Bladder Cancer and Abel Zeta in non-small cell lung cancer. We additionally have an IST study running at the Fred Hutchinson Cancer Center, plus an IST that wrapped up recently at Stanford. Stanford University recently published data from their IST in the peer review Journal of the American Society of Hematology, Blood. The online manuscript has been posted and will appear in print shortly. Stanford reported data showing a doubling of recurrence-free survival at 12 months when NKTR-255 was combined with their investigational CD1922 CAR-T therapy versus historical controls who received their investigational therapy alone. Alongside these studies, Mary will discuss more on the other studies for NKTR-255 and how strong the data is in supporting combination with cell therapies. With the data that's come in during this year, our view is that NKTR-255 has the potential to be a meaningful piece of cancer cell therapy, and we're still assessing opportunities for a strategic partner on that program. Before passing things to JZ, I'd simply note that Nektar's financial footing stays solid, with a cash runway reaching into Q3 of 2026, which leaves us with over one year of cash when REZPEG's top line data come out; so with that, let me turn the call to JZ for the R&D discussion. JZ?

Jonathan Zalevsky

executive
#3

Thanks, Howard. Let me start with REZPEG. In this space, it's the most advanced IL-2 T-reg mechanism around. We see significant potential for REZPEG in atopic dermatitis as well as alopecia areata. From our Phase Ib trial in atopic dermatitis, the data showed efficacy that scaled with dose and durability that was encouraging, seen well after the 12-week induction period ended. In fact, across both patient-reported outcomes and physician-assessed endpoints, the trends matched: quick onset of effect, dose dependence, and prolonged durability of control. That fast onset and the extended disease control seen after dosing stopped matches or beats dupilumab or JAK inhibitors. Given how encouraging these findings are, we and KOLs share a lot of excitement about REZPEG possibly delivering durable responses with less frequent upkeep dosing in atopic dermatitis. Right now, our Phase IIb atopic dermatitis study is enrolling roughly 400 participants and comparing 3 separate REZPEG dosing schedules with placebo, with assessment spanning a 16-week induction phase. After induction concludes, those who meet a threshold allowing them to advance from induction into maintenance are rerandomized to 1 of 2 maintenance schedules at the same dose level they started on, getting that dose either monthly or as part of a once every 3-month regimen. To put our program in the strongest position for registration, we recently changed the protocol so that patients spend more time receiving treatment during the maintenance stage of this trial. At first, the maintenance phase in Phase IIb had been set up to run for 26 weeks of treatment, but that has since been lengthened to 36 weeks, meaning patients in this trial now receive 52 weeks of treatment altogether. This strengthens how solid our data set is, thanks to long-term exposure in this disease setting, and raises how many patients are included in our safety analysis to back registrational trial work that comes after this Phase II study. In addition, we lengthened the off-treatment follow-up so that it spans a 1-year period, beginning once the 52-week treatment period wraps up, allowing us to assess the possible remitted effect of REZPEG in patients following 1 year of treatment. Howard already mentioned this, and we're still on track for top line results covering the 16-week induction phase of the Phase IIb trial during the first half of 2025. Meanwhile, findings from the study's 36-week maintenance phase should come in either near the close of 2025 or at the start of 2026. Switching over to alopecia areata now — this is a dermal condition confined to the hair follicles. What happens here is that a patient's immune system launches an attack on the hair follicle, interfering with the follicle's usual capacity to retain and produce hair, which results in hair loss. Given how T-regs factor into the pathology driving this condition, we see a compelling rationale for REZPEG in treating it. Healthy hair follicles enjoy what's called immune privilege. Basically, that means the inside of the follicle has virtually no immune cells, hardly any MHC expression, and very few immune system pieces at all. We understand that excluding the immune system is essential, because it lets stem cells remain healthy, survive for many years, and continue generating hair over the course of someone's life. In alopecia areata, however, the immune privilege within the follicle breaks down, immune cells infiltrate, inflammation takes hold, and the consequence of all this is hair loss and eventually complete baldness. From a biological standpoint, REZPEG, acting through its central mechanism of T-reg rescue, is uniquely positioned to tackle the wide range of immunopathology involved, which gives it broad potential for treating alopecia areata along with other skin diseases. In preclinical work that has been published, covering both in vitro experiments and mice engrafted with human alopecia skin samples, those studies demonstrated that T-regs play an indispensable role in bringing back and preserving immune privilege, making this a novel therapeutic approach for treating the disease. As a result, we think REZPEG's T-reg mechanism is capable of restoring immune privilege and may deliver lasting disease control. For the patients in this group, there's a major gap when it comes to treatments that are both well tolerated and able to produce lasting results—something current options like JAK inhibitors simply can't offer. That's where we believe R REZPEG could come in, potentially becoming an innovative and even transformative biologic approach for alopecia areata. Enrollment for the Phase IIb trial is moving along nicely, with a target of 84 participants suffering from severe to very severe forms of the condition, who will be assigned randomly to receive either REZPEG or a placebo. The treatment phase lasts 36 weeks, and patients will be followed for as long as 60 weeks overall. For the primary endpoint, we're measuring the average percentage change in the severity of alopecia tool score at the 36-week mark. We're also going to look at several additional secondary endpoints, including how many patients demonstrate different levels of improvement on the salt score. People are enrolling in this trial at a good pace, and we expect top line data sometime around the midpoint of 2025 — that's a few months following the top line readout we'll get from our atopic dermatitis study. Moving on now to NKTR-0165, which is our TNFR2 agonist antibody. TNFR2 shows high expression on T-regs, myeloid suppressor cells, regulatory B cells, neuronal cells and <<inaudible>>; within T-regs, it's been demonstrated that TNFR2 agonism can strengthen effector function, suppressive function and the maintenance of T-reg linear stability, particularly in the non-lymphoid tissue compartment. Research in genetics indicates that when TNFR2 isn't there, the resulting phenotype includes autoimmunity along with additional disorders resembling what you'd see with FOX-P3 loss of function. On the other hand, when it is present and its signaling gets activated, that's been tied to immunoregulatory activity and effects that protect tissue. Our TNS-R2 agonist initiative rests on a great deal of T-reg knowledge accumulated through our work with REZPEG. An agonist of the IL-2 receptor pathway, REZPEG triggers JAK-STAT signaling within T-regs, and that signaling is essential for driving T-reg proliferation and function in both primary and secondary lymphoid organs. TNFR2 stands out as the TNF superfamily member found in the greatest amounts on T-regs, and it serves as the primary activator of NF-kB, which additionally regulates expression of the FOX-P3 protein and plays an essential role in preserving T-reg function, particularly within non-lymphoid organs. So, through the REZPEG and TNFR2 agonist programs, the pipeline at Nektar offers a target rationale covering both lymphoid and non-lymphoid T-reg, which explains our strong enthusiasm for NKTR-0165. As Howard noted, we shared the initial preclinical findings for this program at EULAR back in June of this year. During that presentation, we showed multiple novel and innovative characteristics of the antibodies we found and are now developing. First, the TNFR2 agonist we found came out of De Novo design powered by AI. Because of that, they provide new ways of binding TNFR2 together with cell signaling characteristics. One example of this newness is proof that such antibodies are capable of signaling through the multimeric TNFR2 receptor while in a single-arm monovalent antibody form. For an agonistic antibody targeting TNFR2, that effect is remarkably novel; we put these into a typical bivalent antibody structure, which is NKTR-0165, and demonstrated how extraordinarily specific this antibody is when it comes to binding and signaling via TNFR2 on T-reg. There is nearly no binding or signaling in ordinary T cells and K cells or monocytes. NKTR-165 also caused T-regs to multiply, increased FOX P3, and boosted other activation markers in primary human T-regs. Importantly, NKTR-0165 achieved this on its own, without needing CD3 ligation, costimulation, cytokines, or mitogens. We then studied NKTR-0165 in a human TNFR2 knock-in mouse, using that model to confirm the antibody's T-reg-selective PK/PD profile, and we demonstrated single-agent efficacy in a KLH-DTH mouse model developed within the same TNFR2 knock-in mouse line. We're very excited about the distinctive, differentiated profile of the antibodies we found, and we're moving NKTR-0165 rapidly toward the clinic. We expect to begin first-in-human trials in the middle of 2025. Possible target indications cover multiple sclerosis, mucosal immunology conditions like ulcerative colitis, along with GI or other oral mucosal diseases, plus lupus and dermal autoimmune diseases such as Vitiligo. There's growing interest in a selective, novel TNFR2 agonist like NKTR-0165, and while our IND-enabling studies move ahead, we'll stay open to working with partners who care about these spaces so we can map out the strongest route forward. With that, I'll pass things to Mary for NKTR-255. Mary?

Mary Tagliaferri

executive
#4

Thank you, JZ. And last, let's discuss NKTR-255, our IL-15-based oncology program. We think this IL-15 mechanism of action holds encouraging promise in combinations, especially alongside cell therapies. Although autologous CAR-T cell therapy revolutionized care for large B-cell lymphoma patients once the first cellular therapies gained approval, clinical responses weren't lasting, and about 60% of those who get CAR-T cell therapy for large B-cell lymphoma ultimately progress. Back in 2017, the NCI and Kite, and a month afterward the Fred Hutch Group, released data demonstrating that elevated serum IL-15 levels correlated with greater Cmax and AUC of CAR-T cells, and both of those factors tracked with responses in lymphoma. So our early development approach focused on boosting the long-term efficacy of CAR-T cell products by giving exogenous IL-15, given how much data exists on the significance of this cytokine. Dr. Cameron Turtle of Fred Hutch finished preclinical work demonstrating that NKTR-255 improved in vivo persistence and antitumor efficacy of CD19-directed CAR-T cells in a dose-dependent fashion. As expected, mice given the combination of CAR-T cells plus NKTR-255 sustained noticeably higher peak CAR-T cell levels along with continued tumor suppression, which translated into durable efficacy. After Dr. Turtle's results appeared in Blood Advances, we all held a firm belief that dosing NKTR-255 in patients could drive re-expansion of CAR-T cells and thereby boost efficacy. Fred Hutch launched an IST assessing NKTR-255 as an adjuvant to CAR-T cells to raise the complete response rate among large B-cell lymphoma patients. Dr. Crystal Mackall and Dr. Lory Muffly also studied NKTR-255 for enhancing the efficacy of Stanford's proprietary CD19/22 CAR-T cell in B-cell acute lymphoblastic leukemia. Stanford's data came out in Blood last month. Relative to Stanford's control group that had previously received the CAR-T cell therapy alone, adding NKTR-255 to the CD19/22 CAR-T cell therapy lifted 12-month relapse-free survival from 38% to 67%. For the CAR-T cell only cohort, median RFS was 3.9 months. And for the group given NKTR-255 plus the proprietary CAR-T cell therapy, that median hasn't been reached, with more than 14.4 months of follow-up. So why does NKTR-255 work? We've now confirmed in patients the re-expansion of CAR-T cells after NKTR-255 that we'd seen preclinically. In the Stanford study, we saw re-expansion of the CAR-T cells in the CNS after NKTR-255 administration. At Fred Hutch, where NKTR-255 is being combined with BAVENCIO in large B-cell lymphoma patients, we've confirmed re-expansion of the CAR-T cells following NKTR-255 as well, producing a second peak and a rise in AUC. Another finding from Stanford hints that NKTR-255 also affects lymphocyte trafficking to disease tissues. As you're aware, we've been conducting our own trial, having enrolled 15 patients with large B-cell lymphoma; in that study, NKTR-255 is given after autologous CD19 CAR-T cell therapy. We're wrapping up treatment for the patients who were randomized in our study, and at this point we've seen the same re-expansion phenomenon of CAR-T cells after NKTR-255 treatment in a third trial as well, and we're eager to share the complete data set from this study at an upcoming medical meeting. This compounding effect could have relevance beyond CAR-T cell therapies. Our collaboration continues with AbelZeta, a top cell therapy company, to assess NKTR-255 together with their tumor-infiltrating lymphocytes, or TILs, in a Phase I clinical trial that is ongoing in patients with advanced non-small cell lung cancer who don't respond to anti-PD-1 therapy. Finally, we're still working with Merck KGaA, which is running the Phase II JAVELIN Bladder Medley study, evaluating NKTR-255 in combination with BAVENCIO. Merck expects the first potential PFS analysis from this study around the end of this year. As a reminder, this study has 3 separate combinations under evaluation, each compared separately against the BAVENCIO monotherapy arm; and with that, I'll hand the call over to Sandra for a review of our financial guidance. Sandra?

Sandra Gardiner

executive
#5

Thanks, Mary, and good afternoon, everyone. We closed out the second quarter with $290.6 million in cash and investments, and our balance sheet carries no debt. Our financial position is still solid, and we continue to expect to finish 2024 with $200 million to $225 million in cash and investments. Our cash runway reaches into the third quarter of 2026, which carries us across a number of important data milestones, among them top line data for both our Phase IIb REZPEG study. I'll now quickly go over our quarterly financials and restate our financial guidance for 2024. Revenue came in at $23.5 million for the second quarter of 2024. We continue to expect full-year revenue to fall between $75 million and $85 million, which includes $55 million to $65 million in noncash royalties along with $20 million to $25 million in product sales. For the back half of the year, we expect the remaining revenue to skew more heavily toward the fourth quarter. R&D expense for the second quarter of 2024 came to $29.7 million, and we still expect full-year R&D expense to fall in the range of $120 million and $130 million. G&A expense for the second quarter of 2024 was $20.5 million; we continue to expect full-year G&A expense to land between $70 million and $75 million. Finally, our 2024 noncash interest expense is unchanged and is projected to fall between $20 million and $25 million; in Q2, we booked $13.3 million in noncash impairment charges tied to our real estate obligations, driven by the ongoing decline of the San Francisco Life Sciences and office real estate markets. Our net loss for the second quarter of 2024 was $52.4 million, or $0.25 basic and diluted loss per share. Leaving out the $13.3 million in noncash impairment charges, net loss on a non-GAAP basis came to $39.1 million, or $0.19 basic and diluted loss per share. And as I said earlier, we continue to expect to finish 2024 with $200 million to $225 million in cash and a runway reaching into the third quarter of 2026. And with that, I'll now open the call for questions. Crystal?

Jay Olson

analyst
#6

Nice work on everything moving forward. The NKTR-255 results from the Stanford partnership look excellent. Could you discuss what comes next? And whether NKTR-255 might work synergistically with CAR-T in treating autoimmune diseases.

Howard Robin

executive
#7

Jonathan, would you like to handle that one?

Jonathan Zalevsky

executive
#8

Okay, thank you, Jay, for asking that. I'll kick things off, and Mary, perhaps you could also provide a bit of additional perspective on this. In my view, that Stanford trial mattered a great deal to us, Jay, since it marked the initial occasion when the therapy was assessed quite near to when the CAR was given, correct? Only a brief gap of 2 weeks separated the CAR infusion from when NKTR-255 was administered. And we saw several highly encouraging results that the Stanford Group published. These encompassed alterations in cellularity, shifts in migration—among them, in 1 patient who had CNS disease, with a substantial quantity of CAR trafficking into the CNS, which genuinely benefited that individual—and then, naturally, the length of response, as Mary mentioned, regarding the actual magnitude of benefit seen compared with what has traditionally been known for that CAR, or how long the impact lasts. Mary, perhaps you might speak from a medical standpoint about providing further background and how this aligns with the other trials currently underway.

Mary Tagliaferri

executive
#9

You've got it right, Jay — this is Mary speaking. What's really exciting for us is that we've got three distinct studies running now. We set out to look at safety, feasibility, and efficacy, which would let us determine the Phase III dose we should recommend. Across all three of those trials, we haven't seen any dose-limiting toxicity; instead, the safety profile we're seeing stays consistent and is very favorable for patients. Naturally, this is striking when you combine a drug with CAR-T cell therapies. And it's not only possible to administer this drug right after patients receive CAR-T cells in the adjuvant setting — patients can also continue receiving NKTR-255 every 3 weeks, which is very encouraging for them as well. As we think about what comes next and where we might go, I think that by bringing together the data from all 3 trials, we've landed on a recommended Phase III dose. The other area where we're advancing this drug, as I noted, is in combination with TIL therapy. So at present, as everyone is aware, Iovance pairs its TIL therapy with high-dose IL-2, and that approach is really riddled with problems, since tolerating high-dose IL-2 is extremely hard. To get high-dose IL-2, patients must be admitted to the inpatient setting, and in non-small cell lung cancer specifically, among patients who actually got TILs plus high-dose IL-2 in a very small trial, 2 deaths occurred in that study, which Dr. Scott Antonia ran and which appeared in Nature. So my view is that the opportunities in cellular therapy are quite broad, spanning autologous and allogeneic approaches along with CAR-T cells and TILs. Also, we still need to see results from pairing it with the checkpoint inhibitor, and should those results turn out to be persuasive and robust, that opens up another use case for use alongside checkpoint inhibitors.

Howard Robin

executive
#10

On top of that, obviously our focus has moved into inflammation and immune disease. Yet it's clear that the results we have for IL-15 show strong promise when paired with cell therapies. In my view, that could end up being quite significant for where cell therapy goes next. So discussions are underway with several companies, and I'm confident an important partnership can be reached there.

Jonathan Zalevsky

executive
#11

And Jay, JZ here. Regarding your additional question on autoimmune disease — that's a great one, though at this point it's somewhat theoretical. Still, given what the data showed us and what we published at Stanford, as Mary went through, the combined picture of safety plus pharmacodynamic effects suggests it would be workable to include this as well when CAR cell therapy is used for autoimmune disease. Oncology is where our attention sits right now; in theory, though, from first principles, it ought to be achievable.

Chris Shibutani

analyst
#12

Kevin here, filling in for Chris. Nice work on the progress. I just want to zero in on alopecia for a moment. First, a bit of housekeeping: I realize enrollment is proceeding as planned, and the primary completion date on clinicaltrials.gov hasn't changed, but I'm curious about the timeline — is it mid-25% or the first half? Beyond that, how do you view the value proposition against the JAK inhibitors that are already approved? Given the safety profile, that makes sense. What's your approach when discussing efficacy? When it comes to alopecia, will you be looking to match JAK inhibitor efficacy, or is that even necessary?

Howard Robin

executive
#13

I'd like Mary to take that question.

Mary Tagliaferri

executive
#14

Absolutely, Howard. And Kevin, to your point, yes, the alopecia areata trial got underway in March, and we remain on schedule — top line data, based on the enrollment we have as of today, should come in mid-2025. I thought that was an excellent question you raised, namely what defines success in alopecia areata and where we set the bar. As you're aware, JAK inhibitors do work for alopecia areata, and in the trials that were run, the endpoint was measured at 36 weeks of treatment. Before getting into efficacy, there are 2 main concerns dermatologists bring to us. First, there is no durability whatsoever with a JAK inhibitor — the moment patients stop taking it, hair loss begins right away, and it happens very rapidly. Second, naturally, 80% of alopecia areata patients are under age 40. Nobody truly understands what risks a JAK inhibitor might carry. Obviously, the black box warnings cover serious heart-related events such as heart attacks and stroke, along with blood clots and thrombosis, cancer, and serious infections. So there's a broad concern about putting a patient on a JAK inhibitor for their whole life. Those are the problem statements. On efficacy, we think matching something like baricitinib would give us a differentiated compound, because first, we have no association — certainly across our 600 patients treated so far — with these serious side effects; and second, we believe, based on the Phase Ib in atopic dermatitis, that there's potential for a remitted effect or a maintenance regimen that isn't daily the way you see with a JAK inhibitor. Instead, we could potentially dose patients, following a 36-week induction period, at a frequency longer than every 2 weeks during maintenance. We've talked extensively with doctors about even an induction time period, and their view is that it doesn't even matter if these patients take a year to regrow their hair, provided you actually have a biologic offering a remit benefit without so many side effects — that would be critically important. And specifically regarding the Phase III trials with baricitinib, the change at 36 weeks was under 10% for placebo, which is nice. You can run smaller size studies because the placebo effect is low — approximately 30% for the low dose of baricitinib, the 2 milligram per day dose, and about 49% reduction for the high dose of 4 milligrams.

Kambiz Yazdi

analyst
#15

Kambiz here, filling in for Roger. Could you give us the latest on the Lilly litigation?

Howard Robin

executive
#16

Yeah, absolutely. So, as you're aware, talks with Lilly are still ongoing; and based on that outstanding Phase Ib data, it's clear an error in the math occurred, and once we fixed the calculation mistake we found, those results are pretty compelling. Discussions with Lilly continue; we went through mediation. The court instructed us to keep mediating, and we anticipate doing so soon. So naturally, I'm not able to devote much time to — I can't go into specifics regarding active litigation; what I can say is that we are — we strongly feel their conduct has harmed us. And because of that, we'll keep mediating with them.

Andy Hsieh

analyst
#17

The Nature paper is quite fascinating. I'd like to understand how you view the historical controls. Because the study wasn't randomized, there are certain tensions around baseline patient characteristics. The historical control appears perhaps somewhat more heavily pretreated, and the dosing seems a bit lower. So, simply examining those baseline characteristics, how would you describe what's similar and what's different? How alike are those two groups?

Howard Robin

executive
#18

That's a great question — Mary, could you provide some perspective on the Stanford historical controls?

Mary Tagliaferri

executive
#19

Absolutely, Andy. What I want to do first is say a bit about the individual who ran this trial. Crystal Mackall serves as the Founding Director of the Stanford Center for cancer cell therapy, and she truly is one of the godmothers of cell therapy. If you go look at Crystal's Nature paper, she had in fact given doses to 17 patients, rather than the 8 who serve as the control patients in this study. What she did was pick patients whose baseline characteristic traits were comparable, so they could be matched to the patients in this second study. Given her academic background and the enormous experience she has treating ALL patients, you can picture how very, very attentive she was to those baseline characteristic traits, and to burden of disease as well. That's why she picked the control group so meticulously — it's a subset drawn from the overall number of patients he initially reported on in Nature.

Analyst

analyst
#20

I wanted to ask something briefly about the 165. The preclinical data is clearly quite compelling. That said, JZ, perhaps you could share additional detail regarding the 165 — specifically how it binds the T-reg REZPEG while not attaching to the remaining ones present on the CD4 cell, or most of them, since TNFR2 is known to also be expressed on those 2 sales. I'm simply interested in the mechanism at work there.

Jonathan Zalevsky

executive
#21

Of course. Appreciate it, Arthur. Thanks for raising that. Right, one discovery we made is that our antibody clearly displays a certain type of confirmational selectivity when it comes to the epitope it identifies. Within that EULAR poster, a panel was included demonstrating binding toward 2 distinct versions of TNFR2. As you're aware, TNFR2 is mainly a transmembrane receptor, similar to TNF receptor. However, it may additionally be shed via ectodomain shedding involving typical metaproteomes ADAM17, CLEs TNFR2. That process then releases a shed version capable of circulating within the blood. Consequently, we examined how our antibody binds both the surface receptor and the shed version. What we observed is that the antibody attached to the surface receptor at a far, far greater affinity, considerably more strongly, while having hardly any interaction with the shed version. This tells us there is a confirmational specificity, or at least a confirmational element, involved in the binding. To evaluate that, a great deal of biophysical work is underway at present; to begin with, we are mapping both the epitope and the paratope of the antibodies; those experiments continue to run. In addition, we are performing structural modeling through certain computational structural methods in order to evaluate the epitope. After that, our goal is to bring everything together. We may potentially even reach the point of solving the crystal structure of the antibody itself. Still, what we currently hypothesize is that it is highly confirmational. That explains the cellular selectivity we observe, since although you're correct that the receptor appears on numerous cell types, its function differs among those cell types, and likewise the trap components responsible for intracellular signaling are not identical across them; we believe that accounts for it. All the same, yes, we're quite thrilled, because that is — it isn't a typical result, as you might expect for an antibody, which is exactly why we regard this as such an innovative molecule.

Howard Robin

executive
#22

All right, and thanks to each of you for being here with us today. As is evident, we are achieving strong momentum on our strategic plan, which centers Nektar's work on inflammation and immunology. We are also moving several novel and innovative therapies forward, both within and toward the clinic. So I'd like to express appreciation to every one of our employees for their dedication, and to our investors for sticking with us, and please keep watching. Thank you for being with us today.

Operator

operator
#23

Thanks. That wraps up the conference call for today. We appreciate everyone joining us. You're free to hang up now. Have a great day, everybody.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.